**Supplementary Table 9** Etiology-specific therapies and further decompensation outcomes

|  |  |  |  |
| --- | --- | --- | --- |
| **Etiology** | **Therapy Group** | **Number of patients/n** | **Further decompensation events/n(%)** |
| Hepatitis B virus | Antiviral therapy | 38 | 15 (39.47) |
| Untreated | 6 | 2 (33.33) |
| Hepatitis C virus | Antiviral therapy | 7 | 3 (42.86) |
| Untreated | 2 | 0 (0.00) |
| Alcohol-associated | Abstinence | 20 | 5 (25.00) |
| Active drinking | 4 | 1 (25.00) |
| Undetermined statusa | 12 | 4 (33.33) |
| AIH/PBC | Guideline-directed therapy | 31 | 8 (25.81) |
| Other | No etiology-specific therapy | 32 | 14 (43.75) |

a Undetermined status: Abstinence status could not be confirmed through medical record review and structured telephone follow-up.

AIH:Autoimmune hepatitis; PBC:Primary biliary cholangitis.